| Today’s Big NewsMar 10, 2025 |
|
Thursday, April 3, 2025 | 11am ET / 8am PT Join us for an insightful webinar on the latest advancements in cell and gene therapy, focusing on the innovative Cas9-CLIPT (Cleaved, Linearized with Protein Template) technology. Learn more about this groundbreaking technology designed to improve the efficiency of genome editing. Register now. 
|
|
| By Kevin Dunleavy In exercising some of his stock options in 2024, BioNTech CEO Uğur Şahin, M.D., scored a whopping 259.5 million euros in calculated compensation, the company said in its annual report. |
|
|
|
By Nick Paul Taylor Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. Three months after missing that target in its first phase 3 CagriSema trial, the Danish drugmaker has fallen even further short of that bar in the second study. |
By Gabrielle Masson Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program. |
By Angus Liu Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit that the Swiss pharma bought for $4.3 billion in 2019. |
By Angus Liu Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. |
By Nick Paul Taylor Novo Nordisk is rolling out a new national marketing campaign for its GLP-1 juggernaut, teaming up with celebrities and other patients to show what life looks like in their “Ozempic Eras.” |
By Darren Incorvaia Biotech incubator Flagship Pioneering has uncorked its latest company. Lila Sciences is looking to use $200 million in seed funding to develop advanced artificial intelligence that can power fully autonomous research labs. |
By Zoey Becker Activist investor Starboard Value proposed four additions to Kenvue's board last month in an effort to unlock "trapped potential" at the consumer health giant. |
By Darren Incorvaia Boston biotech Beam Therapeutics has announced initial data from a phase 1/2 trial of its gene therapy for a genetic lung and liver disease, with no serious adverse events reported among the nine patients dosed so far. |
By Fraiser Kansteiner Incyte's Opzelura was successful in just one of two parallel phase 3 trials assessing the JAK inhibitor in the skin condition prurigo nodularis. |
By Conor Hale Dexcom has received a warning letter from the FDA, following two inspections of the diabetes tech company's facilities last year. |
By Fraiser Kansteiner The FDA last week approved Neurotech’s cell therapy implant revakinagene taroretcel to treat the vision-robbing neurodegenerative disease macular telangiectasia type 2. The therapy, which will adopt the brand name Encelto, is the first to win the FDA’s blessing in the rare vision disorder. |
By Darren Incorvaia Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. No serious adverse events were tied to the British biotech’s bispecific T-cell engager in a phase 1/2 trial, and the investigational treatment also reduced virus levels in the blood of three patients living with HIV. |
By Nick Paul Taylor The data drops provide more evidence that rocatinlimab improves outcomes in atopic dermatitis, but questions about the positioning of the anti-OX40 antibody versus Sanofi and Regeneron’s Dupixent remain unanswered. |
By Andrea Park Every year, amid Women’s History Month, March 8 marks International Women’s Day—a day dedicated to both honoring past efforts and drumming up greater awareness and support for the ongoing movement toward gender equality. |
By Kevin Dunleavy At the American Academy of Dermatology's annual meeting this weekend, Bristol Myers Squibb revealed promising data from one of two successful late-stage trials of Sotyktu in psoriatic arthritis. The company added that will unveil results of the other trial by the end of this year. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we dig into several of the biggest private funding rounds in biotech last year and discuss the shifting VC landscape. |
|
|---|
|
|
|
Wednesday, April 9, 2025 | 10am ET / 7am PTLearn the key steps for successfully entering Japan’s pharmaceutical market. This webinar covers regulatory requirements, compliance strategies, supply chain best practices, and common challenges. Gain expert insights to navigate this high-potential market with confidence. Don’t miss out—register now to secure your spot! 
|
|
Whitepaper Read about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
Whitepaper Develop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| Submissions Open Early August |
|
|
| |
|
